Repligen Co. (NASDAQ:RGEN) Shares Sold by First Trust Advisors LP

First Trust Advisors LP cut its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 5.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 285,561 shares of the biotechnology company's stock after selling 15,023 shares during the quarter. First Trust Advisors LP owned 0.51% of Repligen worth $41,104,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of RGEN. Signaturefd LLC grew its stake in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares in the last quarter. Sava Infond d.o.o. purchased a new position in Repligen in the fourth quarter worth about $29,000. UMB Bank n.a. increased its stake in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Global Retirement Partners LLC raised its position in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Repligen in the 4th quarter valued at approximately $55,000. Institutional investors own 97.64% of the company's stock.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.20% of the company's stock.

Repligen Stock Down 0.3 %

Shares of RGEN stock traded down $0.48 during mid-day trading on Friday, hitting $144.75. 439,931 shares of the stock traded hands, compared to its average volume of 712,103. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market cap of $8.13 billion, a P/E ratio of -283.82, a P/E/G ratio of 4.54 and a beta of 1.27. The stock's fifty day moving average is $139.80 and its two-hundred day moving average is $145.79. Repligen Co. has a 52-week low of $102.97 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Equities analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RGEN. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a report on Thursday, April 17th. Finally, Canaccord Genuity Group decreased their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of "Hold" and an average target price of $176.82.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.